Immunotherapy for recurrent or metastatic HNSCC: What are the practical considerations? - touchONCOLOGY
Royal Marsden researchers named among world's most influential scientists | The Royal Marsden
ICR Discovery Club showcases how we combine therapies to target hard-to-treat cancers - The Institute of Cancer Research, London
Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI - YouTube
Scientists reveal new lines of attack to raise cancer survival rate | Cancer research | The Guardian
Connections blog - ICR celebrates innovation and commercialisation at staff awards - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Using imaging to predict and improve responses to immunotherapy - Oracle Cancer Trust
Professor Kevin Harrington - The Institute of Cancer Research, London
Scientific Lecture | Kevin Harrington | FRONTAL
SAB and I-O AB - T3 Pharma
The ICR on Twitter: "Professor Kevin Harrington explained the basic principles of using viruses to treat cancer and talked about the cancer-killing virus therapy, T-VEC. Find out more about how viral immunotherapies
ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London
The Institute of Cancer Research - Professor Kevin Harrington (ICR + Royal Marsden NHS Foundation Trust) responds to today's news of the 2018 Nobel Prize for Physiology or Medicine being awarded to
The ICR on Twitter: "We were delighted to welcome @JonAshworth (MP & Shadow Health Secretary) to visit us today with @CRUK_Policy to meet Professor Kevin Harrington and team. Jon saw some of
Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London
High-tech radiotherapy, drug combinations and immunotherapy showcased as future of cancer treatment - The Institute of Cancer Research, London
Histological and functional studies of isolated arteries containing contrast agents exposed to high intensity focused ultrasoun
Cancer: Scientists aim to double survival within a decade | The Independent
The ICR on Twitter: "Today, Prof. Kevin Harrington (ICR/@cancerBRC) will present on a trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined
Cancer survival 'to double in 10 years' - PressReader
Connections blog - ICR celebrates innovation and commercialisation at staff awards - The Institute of Cancer Research, London
The ICR on Twitter: "ICR's Professor Kevin Harrington speaks about the @NICEcomms news about immunotherapy #nivolumab https://t.co/pRd7KUmAmR #CancerDrugsFund https://t.co/ompikxJVHr" / Twitter
The ICR on Twitter: "Professor Kevin Harrington specialises in #HeadAndNeckCancer. He and his team study the use of biologically targeted agents, in combination with treatments such as #Radiotherapy and #Chemotherapy, to target #
The ICR on Twitter: "🧬 The ICR's Professor Kevin Harrington and his team are using viral #Immunotherapy to harness the body's immune system to kill cancer. See their research with T-VEC, a
